Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476775 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL30037693 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL18917031 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL666140 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL30801428 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL417576 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL29388642 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL30059530 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL128589 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL3161061 | 1.00 | NAAA (0.57) | NAAAEPHX1TSHRHCAR2RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239836-A9 | LIPIDS, NANOPARTICLES COMPRISING THE SAME AND USES THEREOF | ACADEMIA SINICA (TW) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023239836-A1 | LIPIDS, NANOPARTICLES COMPRISING THE SAME AND USES THEREOF | ACADEMIA SINICA (TW) | 2023-12-14 | — | — | WO | disclosed |
| US-20230159459-A1 | NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | GENERATION BIO CO. | 2023-05-25 | — | — | US | disclosed |
| CN-110382494-A | Substituted pyrazolo [1,5-A ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-110105346-A | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2019-08-09 | — | — | CN | disclosed |
| CN-106414432-B | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2019-06-14 | — | — | CN | disclosed |
| CN-106414432-A | Optionally substituted quinoline compounds | 卫材R&D管理有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-104640863-B | Pyrimidinamine derivatives and its preparation method and application | 山东亨利医药科技有限责任公司 | 2016-06-08 | — | — | CN | disclosed |
| CN-103492377-B | As the triazolopyridine compounds of PIM kinase inhibitor | ARRAY BIOPHARMA INC. (US) | 2016-04-20 | — | — | CN | disclosed |
| CN-105209457-A | Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE DEUTSCHLAND | 2015-12-30 | — | — | CN | disclosed |
| CN-104540834-A | Novel thienopyrimidine derivatives, preparation method and therapeutic use thereof | SANOFI SA | 2015-04-22 | — | — | CN | disclosed |
| CN-103492377-A | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC | 2014-01-01 | — | — | CN | disclosed |
| CN-102918043-A | Pyrrolopyrimidine compounds as CDK4/6 inhibitors | NOVARTIS AG | 2013-02-06 | — | — | CN | disclosed |
| EP-1311018-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY | UBE INDUSTRIES (JP) | 2011-10-12 | — | — | EP | disclosed |
| CN-1863804-B | Certain substituted spirocyclic lactams and their use as pharmaceuticals | NOVARTIS AG | 2010-05-26 | — | — | CN | disclosed |
| CN-1863804-A | Certain substituted spirocyclic lactams and their use as pharmaceuticals | NOVARTIS AG (CH) | 2006-11-15 | — | — | CN | disclosed |
| US-6881522-B2 | Nonaqueous electrolytic solution and lithium secondary battery | UBE INDUSTRIES, LTD. (JP) | 2005-04-19 | — | — | US | disclosed |
| CN-1596253-A | Spiro-hydantoin compounds useful as anti-inflammatory agents | BRISTOL MYERS SQUIBB CO (US) | 2005-03-16 | — | — | CN | disclosed |
| US-20040058251-A1 | Nonaqueous electrolytic solution and lithium secondary battery | HAMAMOTO TOSHIKAZU (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1311018-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY | Ube Industries, Ltd. (JP) | 2003-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159459-A1 | NOVEL LIPIDS AND NANOPARTICLE COMPOSITIONS THEREOF | LIPG, NPC1L1, NPC1 | NAAA 579/4885EPHX1 1787/4885TSHR 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.